Latest news with #ISR
&w=3840&q=100)
First Post
a day ago
- First Post
Watch: China showcases OW5 laser weapon in ‘border control' exercise
Chinese media highlighted laser weapons' ability to instantly destroy targets with unlimited ammunition, dependent on the power supply read more China on Monday (July 21) conducted a warfare demonstration showcasing a wide array of uncrewed systems, in an attempt to position itself as a major global drone supplier. State media CCTV reported that the exercise was held at an Inner Mongolia testing ground, and it simulated the 'seizure and control of critical border locations.' The drill featured six phases of a futuristic battlefield scenario, including reconnaissance, AI planning, infiltration, aerial attack, elimination, and anti-access, deploying various Chinese-made systems. STORY CONTINUES BELOW THIS AD Burning out drone circuits in seconds! China's OW5 laser weapon system, displayed Monday in North China's Inner Mongolia, is a high-mobility, vehicle-mounted, low-altitude anti-drone system. It can rapidly switch targets after taking one down. — Global Times (@globaltimesnews) July 22, 2025 Displayed unmanned aerial vehicles (UAVs) included ISR drones, long- and short-range loitering munitions, uncrewed helicopters, and tactical first-person view (FPV) devices. Ground systems, such as smart command-and-control units and anti-drone defences, were also showcased. A rare live-fire demonstration featured the OW-5 anti-drone laser weapon, whose 'high-energy beam barely visible to bare eyes' downed a drone 'a few kilometres away,' CCTV reported. Unveiled statically at the 2021 Zhuhai air show, the upgraded OW5-A50, with a 50-kilowatt output, integrates command-and-control, radar, sensors, and a laser gun on an 8x8 Dongfeng truck, enabling standalone or networked air defence. CCTV highlighted laser weapons' ability to instantly destroy targets with unlimited ammunition, dependent on the power supply. The exercise demonstrated drone-artillery coordination, with a 155mm howitzer engaging targets using real-time UAV-transmitted coordinates. Small tactical drones, including a flying jammer disrupting electro-optical equipment over several kilometres, were also featured. Notable drones included the Flying Frog (VTOL reconnaissance), Flying Falcon (high-speed loitering munition), Black Bee (grenade-throwing), and Flying Whale (bomb-dropping). STORY CONTINUES BELOW THIS AD 'With these smart partners, our infantry soldiers can evolve into future nodes with full-domain situational awareness and precision strikes, to win by intelligence on the modern battlefield,' CCTV stated. Norinco, China's largest arms manufacturer and exporter, organised the event, unveiling its Feilong (Flying Dragon) loitering munitions family. The series includes the anti-personnel Feilong-10, with a range under 10km, and the Feilong-300A, an anti-radiation drone targeting air defence radars up to 300km away. The Feilong-60 serves as a reconnaissance source or hoverable cruise missile, launchable from rocket systems, while the Feilong-30 adapts to trucks, vehicles, or ships. These drones can form a networked swarm for saturated attacks, per CCTV.
Indian Express
2 days ago
- Politics
- Indian Express
5,100 houses demolished by DDA in three years, 3,000 households rehabilitated: Minister tells Rajya Sabha
A total of 5,185 houses were demolished in the Capital in the action taken by Delhi Development Authority (DDA) in the last three years, Union Minister of State for Housing and Urban Affairs Tokhan Sahu told Rajya Sabha on Monday. Of these, 3,043 households — and effectively 17,015 people — have been provided with alternative rehabilitation in the form of flats in Ashok Vihar, Kalkaji and Narela. According to Sahu, who provided the details in response to a question, the DDA has spent Rs 766 crore (excluding land cost) in building housing for the rehabilitation of slum dwellers. Considering an average household size of five, an estimated 25,000 people have been displaced due to such demolitions. A total of 1,896 households from the Bhoomiheen Camp in Kalkaji were allotted flats in the In-situ Rehabilitation (ISR) project at Kalkaji Extension. From slum clusters in Jailorwala Bagh in Ashok Vihar, Golden Park, Rampura, and Mata Jai Kaur, 1,404 households have been rehabilitated to the Swabhiman Apartments in Ashok Vihar. From a JJ cluster at Kalibari near RML Hospital, 103 families have been rehabilitated in Narela. The rehabilitation of slums in the city is governed by the Delhi Slum & Jhuggi Jhopri Rehabilitation and Relocation Policy, 2015, which was approved by the Cabinet in 2016. It prioritises in-situ rehabilitation to ensure alternative accommodation to a slum dweller on the same land or within a 5 km radius. To be eligible for rehabilitation, however, the slum must have at least 50 households, must have existed before 2006, and the slum dweller must prove residence in the slum before 2015. 'The transition from jhuggi living to life in a modern flat, cohesive group living, sense of community ownership of common resources like common area, lift, etc. and adapting to the changes' were the main challenges faced by slum dwellers in the rehabilitation process, according to the reply. There are 675 slum clusters in Delhi, according to the Delhi Urban Shelter Improvement Board (DUSIB). Of these, 376 occupy Central government land and come under the DDA's jurisdiction. DUSIB is responsible for rehabilitating the remaining 299 JJ clusters located on Delhi government land. Political parties estimate that roughly 50 lakh people, or close to a quarter of the total population, live in slums in the national capital. Devansh Mittal is a trainee correspondent with The Indian Express. He studied political science at Ashoka University. He can be reached at ... Read More
Cision Canada
2 days ago
- Business
- Cision Canada
Denison Announces Additional High-Grade Uranium Mineralization Discovered at McClean South
TORONTO, July 21, 2025 /CNW/ - Denison Mines Corp. ("Denison" or the "Company") (TSX: DML) (NYSE American: DNN) is pleased to announce that several significant new intercepts of shallow high-grade uranium mineralization have been discovered at the McClean South zone ("McClean South"), which is part of the Company's 22.5%-owned McClean Lake Joint Venture ("McClean Lake" or "MLJV") in northern Saskatchewan (see Figure 1). PDF Version View PDF Orano Canada Inc. ("Orano Canada"), the 77.5% owner and operator of the MLJV, completed a 6,400-metre exploration drilling program at McClean South during the first half of 2025. The drill program was highlighted by multiple notable high-grade intersections at the 8C mineralized pod: MCS-77 intersected 7.5 1 % eU 3 O 8 over 5.4 metres from 165.7 to 171.1 metres (including 10.88% eU 3 O 8 over 3.7 metres), MCS-80 intersected 3.5% eU 3 O 8 over 11.2 metres from 156.7 to 167.9 metres (including 5.81% eU 3 O 8 over 6.5 metres), and MCS-84 intersected 1.7 2 % eU 3 O 8 over 20.6 metres from 150.6 to 170.7 metres (including 4.43% eU 3 O 8 over 4.0 metres) In total, fourteen of twenty-four completed drill holes from the program encountered significant intercepts of uranium mineralization and the results are interpreted to have confirmed and expanded the mineralized footprint of the 8C and 8W pods (see Figure 2 and 3). McClean South is located approximately 600 metres to the south of the McClean North deposit, where the MLJV recently commenced commercial mining using the joint venture's patented SABRE mining method. Chad Sorba, Denison's Vice President of Technical Services and Project Evaluation, commented "Earlier this year, in its effort to follow up on the discovery of the 8C pod at McClean South since the last drill program in 2022, Orano Canada carried out a successful exploration program that returned several meaningful additional high-grade intercepts, which are interpreted to have expanded the mineralized footprint of the 8C and 8W pods." David Cates, Denison's President & CEO, added "We congratulate and thank Orano Canada for its efforts to successfully advance the delineation and expansion of the high-grade mineralization at McClean South. With the nearby McClean North deposit recently entering production using the joint venture's SABRE mining method and Denison having made significant advancements in the de-risking of the In-Situ Recovery ('ISR') mining method in recent years, there is great potential for the MLJV to advance McClean South to potentially emerge as an economic new source of future feed to the McClean Lake mill." 2025 McClean South Exploration Highlights The objective of the exploration program at McClean South was to expand the existing footprint of high-grade mineralization with a focus on further assessing the 8C and 8W Pods. With uranium mineralization measuring greater than 0.05% eU (0.06% eU 3 O 8) intersected in 14 of 24 drill holes completed during the program, the results successfully expanded the footprint of the 8W and 8C pods and confirmed the continuity of mineralization. Results from the 8W pod were highlighted by the following: MCS-61 and MCS-64 confirmed mineralization in the sandstone near surface along the western edge of the 8W pod. MCS-61 intersected 0.15% eU 3 O 8 over 2.2 metres from 40.3 to 42.5 metres and MCS-64 intersected 0.21% eU 3 O 8 over 1.2 metres from 57.6 to 58.8 metres. The results of the holes discussed above and the balance of the mineralized intersections from the 2025 drill program are summarized in Table 1 below. Table 1 – 2025 McClean Lake Exploration Drilling – Mineralized Intersections Notes: (1) Lengths indicated represent the down-hole length of mineralized intersections; (2) Interval is composited above a cut-off grade of 0.05% eU, which corresponds to 0.06% eU 3 O 8 Radiometric Equivalent Grades, Sampling, Analysis and Data Verification Following the completion of a drill hole, the hole is radiometrically logged using a downhole slimline gamma probe, which collects continuous readings of radioactivity along the length of the drill hole. Probe results are then calibrated using an algorithm calculated from the comparison of probe results against geochemical analyses in the area. The gamma-log results provide an immediate radiometric equivalent uranium value (eU%, then converted to eU 3 O 8 %) for the hole, which, except in very high-grade zones, is reasonably accurate. The Company typically reports eU 3 O 8, as a preliminary result and subsequently reports definitive assay grades following sampling and chemical analysis of the mineralized drill core. Assay sample intervals are generally 50 centimetres long, except where higher or lower grade mineralization boundaries fall within the interval. In that case, two 25-centimetre samples are collected. Flank samples of 1.0 metre are collected where mineralization is located. Systematic geochemistry samples are collected every 10 metres down the hole. All assayed core is split in half, with one half retained and the other sent to the SRC Geoanalytical Laboratory in Saskatoon for analysis. Control samples are routinely assayed with each batch of core samples analyzed. About McClean South 8C, 8E and 8W Pods The McClean South trend is located parallel to and approximately 600 metres south of the McClean North trend in the southwestern portion of the property (see Figure 1). The McClean South zone has been the subject of historic exploration drilling, resulting in the discovery and subsequent delineation of the 8W, 8C, and 8E pods, which are situated along a N70° to 80° trend near the McClean Lake granitic dome to the south (see Figure 2 and 3). Mineralization within the 8W, 8C and 8E pods is currently understood to be primarily hosted within the sandstone; however, it has been locally encountered within the basement of the 8W and 8C pods. The mineralization within the sandstone can extend upwards of 50 meters above the unconformity and has been identified near surface at the western edge of the 8W pod. No current resource estimate, prepared in accordance with NI 43-101, exists for the mineralization identified to date at the McClean South pods. About McClean Lake The McClean Lake property is located on the eastern edge of the Athabasca Basin in northern Saskatchewan, approximately 750 kilometres north of Saskatoon. Denison holds a 22.5% ownership interest in the MLJV and the McClean Lake uranium mill, one of the world's largest uranium processing facilities. The mill has licensed annual production capacity of 24.0 million pounds U 3 O 8 and is currently operating under a 10-year license expiring in 2027. The mill is contracted to process the ore from the Cigar Lake mine under a toll milling agreement (up to 18.0 million pounds U 3 O 8 per year). The MLJV is an unincorporated contractual arrangement between Orano Canada with a 77.5% interest and Denison with a 22.5% interest. Orano Canada is the operator of the project. McClean Lake consists of nine known uranium deposits: JEB; Sue A, B, C, D, E and F; McClean North; and McClean South. In 1995, the development of the McClean Lake project began. Mill construction commenced in 1995, and ore processing activities reached commercial production in November 1999. Mining operations commenced in 1996, and the following deposits have been mined out to date: JEB (1996 to 1997), Sue C (1997 to 2002), Sue A (2005 to 2006), Sue E (2005 to 2008) and Sue B (2007 to 2008). Production from the McClean North deposit, using the MLJV's patented SABRE mining method, commenced in 2025. About Denison Denison is a leading uranium mining, development, and exploration company with interests focused in the Athabasca Basin region of northern Saskatchewan, Canada. Denison has an effective 95% interest in its flagship Wheeler River Uranium Project, which is the largest undeveloped uranium project in the infrastructure rich eastern portion of the Athabasca Basin region of northern Saskatchewan. In mid-2023, the Phoenix feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have the potential to be competitive with the lowest cost uranium mining operations in the world. Permitting efforts for the planned Phoenix ISR operation commenced in 2019 and several notable milestones were achieved in 2024 with the submission of federal licensing documents and the acceptance of the final form of the project's Environmental Impact Statement by the Province of Saskatchewan and the Canadian Nuclear Safety Commission. Denison's interests in Saskatchewan also include a 22.5% ownership interest in the MLJV, which includes unmined uranium deposits (with mining at the McClean North deposit via the MLJV's SABRE mining method having commenced in 2025) and the McClean Lake uranium mill (currently utilizing a portion of its licensed capacity to process the ore from the Cigar Lake mine under a toll milling agreement), plus a 25.17% interest in the Midwest Joint Venture Midwest Main and Midwest A deposits, and a 70.55% interest in the Tthe Heldeth Túé ('THT') and Huskie deposits on the Waterbury Lake Property. The Midwest Main, Midwest A, THT and Huskie deposits are located within 20 kilometres of the McClean Lake mill. Taken together, Denison has direct ownership interests in properties covering ~384,000 hectares in the Athabasca Basin region. Additionally, through its 50% ownership of JCU (Canada) Exploration Company, Limited ('JCU'), Denison holds interests in various uranium project joint ventures in Canada, including the Millennium project (JCU, 30.099%), the Kiggavik project (JCU, 33.8118) and Christie Lake (JCU, 34.4508%). In 2024, Denison celebrated its 70th year in uranium mining, exploration, and development, which began in 1954 with Denison's first acquisition of mining claims in the Elliot Lake region of northern Ontario. Qualified Persons The technical information contained in this press release has been reviewed and approved by Chad Sorba, Denison's Vice President Technical Services & Project Evaluation, who is a Qualified Person in accordance with the requirements of NI 43-101. Cautionary Statement Regarding Forward-Looking Statements Certain information contained in this news release constitutes 'forward-looking information', within the meaning of the applicable United States and Canadian legislation, concerning the business, operations and financial performance and condition of Denison. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'expects', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes', or the negatives and/or variations of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur', 'be achieved' or 'has the potential to'. In particular, this news release contains forward-looking information pertaining to the following: the interpretation of exploration results and expectations with respect thereto, including the interpretation of the results from the McClean Lake JV exploration program undertaken by Orano Canada, underlying assumptions and the McClean Lake JV's intentions with respect thereto; exploration plans and objectives; plans and objectives for ISR and SABRE mining by Denison and/or Orano Canada; and expectations regarding its joint venture ownership interests and the continuity of its agreements with its partners and third parties. Statements relating to 'mineral reserves' or 'mineral resources' are deemed to be forward-looking information, as they involve the implied assessment, based on certain estimates and assumptions that the mineral reserves and mineral resources described can be profitably produced in the future. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Denison to be materially different from those expressed or implied by such forward-looking statements. For example, the modelling and assumptions upon which the interpretation of results are based may not be maintained after further testing or be representative of actual conditions. Denison believes that the expectations reflected in this forward-looking information are reasonable but no assurance can be given that these expectations will prove to be accurate and results may differ materially from those anticipated in this forward-looking information. For a discussion in respect of risks and other factors that could influence forward-looking events, please refer to the factors discussed in Denison's Annual Information Form dated March 28, 2025 or subsequent quarterly financial reports under the heading 'Risk Factors'. These factors are not, and should not be construed as being exhaustive. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Any forward-looking information and the assumptions made with respect thereto speaks only as of the date of this news release. Denison does not undertake any obligation to publicly update or revise any forward-looking information after the date of this news release to conform such information to actual results or to changes in Denison's expectations except as otherwise required by applicable legislation. SOURCE Denison Mines Corp.
Yahoo
16-07-2025
- Business
- Yahoo
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
DUBLIN, July 16, 2025--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical studies. The report, based on extensive feedback from 159 industry professionals, underscored ICON's dominance across a wide range of performance metrics and highlights the company's unwavering commitment to innovation, operational excellence, and customer satisfaction. Key highlights from the report include: Sponsor satisfaction: For phase 1 research, ICON outperformed all other large CROs claiming the highest overall sponsor satisfaction score of 7.4 on a scale of 1-10. Outstanding operational metrics: ICON outperformed the average performance score of other large CROs in all 17 operational metrics, with a considerable lead differential in 14. These metrics are grouped into three categories of critical service capabilities including delivery metrics (such as adhering to project timelines), staff characteristics (like therapeutic expertise), and accessibility metrics (clinic availability, for example). Robust brand strength: Across the four brand strength performance metrics of familiarity, leadership, reported recent use, and preference, ICON was the only large CRO to improve its scores across the board compared to ISR's 2024 iteration of this research, with the largest gains in leadership and preference. Consistency of excellence: For six consecutive years, ICON has outperformed the weighted average performance scores of the other large CROs in phase 1 clinical trials, demonstrating sustained excellence and reliability. "ICON's strong results in this report reflect the dedication, expertise, and innovation that drive our teams globally," said Steve Cutler, CEO. "Our consistent leadership in phase 1 clinical trials is a testament to our ability to meet and exceed client expectations, deliver high-quality outcomes, and advance breakthroughs in early-phase development." The benchmarking report used a rigorous methodology to ensure results reflected ICON's true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance of role and responsibility, and mandated a recent interaction with a CRO. The survey data was collected in Q4 2024. For more information, please visit About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: About ISR Market Research: ISR utilises primary research methodologies to offer novel insights into the drug development industry. As an independent market research partner focusing on the life sciences space, ISR helps clients make data-informed decisions with specificity and precision that generalist firms can't match. ISR's analysts are industry experts in their own right with over 15 years of experience in this niche. They also diligently curate membership for ISR's Life Science Panel of respondents. Panel members are from a wide spectrum of geographies and job levels across a variety of roles & responsibilities, and their valuable experiential data informs both ISR's off-the-shelf syndicated reports and robust custom research capabilities. ICON/ICLR-G View source version on Contacts Media contacts: Lisa Henry (GMT time zone)Weber Shandwick (PR adviser)+447785 458203lhenry@ ICON Press Officeiconnews@
Business Wire
16-07-2025
- Business
- Business Wire
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical studies. The report, based on extensive feedback from 159 industry professionals, underscored ICON's dominance across a wide range of performance metrics and highlights the company's unwavering commitment to innovation, operational excellence, and customer satisfaction. Key highlights from the report include: Sponsor satisfaction: For phase 1 research, ICON outperformed all other large CROs claiming the highest overall sponsor satisfaction score of 7.4 on a scale of 1-10. Outstanding operational metrics: ICON outperformed the average performance score of other large CROs in all 17 operational metrics, with a considerable lead differential in 14. These metrics are grouped into three categories of critical service capabilities including delivery metrics (such as adhering to project timelines), staff characteristics (like therapeutic expertise), and accessibility metrics (clinic availability, for example). Robust brand strength: Across the four brand strength performance metrics of familiarity, leadership, reported recent use, and preference, ICON was the only large CRO to improve its scores across the board compared to ISR's 2024 iteration of this research, with the largest gains in leadership and preference. Consistency of excellence: For six consecutive years, ICON has outperformed the weighted average performance scores of the other large CROs in phase 1 clinical trials, demonstrating sustained excellence and reliability. 'ICON's strong results in this report reflect the dedication, expertise, and innovation that drive our teams globally,' said Steve Cutler, CEO. 'Our consistent leadership in phase 1 clinical trials is a testament to our ability to meet and exceed client expectations, deliver high-quality outcomes, and advance breakthroughs in early-phase development.' The benchmarking report used a rigorous methodology to ensure results reflected ICON's true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance of role and responsibility, and mandated a recent interaction with a CRO. The survey data was collected in Q4 2024. For more information, please visit About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: About ISR Market Research: ISR utilises primary research methodologies to offer novel insights into the drug development industry. As an independent market research partner focusing on the life sciences space, ISR helps clients make data-informed decisions with specificity and precision that generalist firms can't match. ISR's analysts are industry experts in their own right with over 15 years of experience in this niche. They also diligently curate membership for ISR's Life Science Panel of respondents. Panel members are from a wide spectrum of geographies and job levels across a variety of roles & responsibilities, and their valuable experiential data informs both ISR's off-the-shelf syndicated reports and robust custom research capabilities. ICON/ICLR-G
